|Day's Range||24.07 - 24.26|
|52 Week Range||15.27 - 24.31|
|PE Ratio (TTM)||40.50|
|Dividend & Yield||0.28 (1.22%)|
|1y Target Est||N/A|
Categories: Yahoo Finance Lonza Group AG relative valuation is now OVERVALUED. It was previously rated NEUTRAL, and has a fundamental analysis score of 67. Our analysis is based on comparing Lonza Group AG with the following peers – Sarepta Therapeutics, Inc., Amgen Inc., Merrimack Pharmaceuticals, Inc. and Arena Pharmaceuticals, Inc. (SRPT-US, AMGN-US, MACK-US and ARNA-US). Relative Valuation Lonza ... Read more (Read more...)
Categories: Yahoo Finance Get free summary analysis Lonza Group AG reports financial results for the half-year ended December 31, 2016. We analyze the earnings along side the following peers of Lonza Group AG – Sarepta Therapeutics, Inc., Amgen Inc. and Merrimack Pharmaceuticals, Inc. (SRPT-US, AMGN-US and MACK-US) that have also reported for this period. Highlights Summary numbers: Revenues ... Read more (Read more...)
The looming foreign takeovers of biotech group Actelion and agrichemicals firm Syngenta look set to trigger the biggest shake-up in the Swiss blue-chip SMI index (.SSMI) in years just as passive investing makes membership increasingly important. Analysts say specialty chemicals group Lonza (LONN.S) may be set to join the Swiss club of the 20 best capitalized and most liquid shares, whose ranks could be thinned even further by the time that the next review takes place in June, analysts say. "It is pretty clear that under the current selection list by the Swiss exchange, Lonza could be taken into the SMI," said Thomas Kuehne, fund manager at Liechtensteinische Landesbank.